Literature DB >> 17565539

Are platinum-based chemotherapeutic drugs safe for patients with Charcot-Marie-Tooth disease?

Ronit Yerushalmi, Itay Levi, Marc Wygoda, Gal Ifergane, Itzhak Wirguin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17565539     DOI： 10.1111/j.1529-8027.2007.00133.x

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN： 1085-9489            Impact factor:   3.494


× No keyword cloud information.
  3 in total

1.  Vincristine exacerbates asymptomatic Charcot-Marie-tooth disease with a novel EGR2 mutation.

Authors:  Tomonori Nakamura; Akihiro Hashiguchi; Shinsuke Suzuki; Kimiharu Uozumi; Shoko Tokunaga; Hiroshi Takashima
Journal:  Neurogenetics       Date:  2012-01-25       Impact factor: 2.660

2.  Effective treatment of advanced Hodgkin lymphoma with a modified BEACOPP regimen for a patient with demyelinating hereditary motor and sensory neuropathy type 1 (HMSN1).

Authors:  Patrick P Hess; Monica S Ventura Ferreira; Benjamin Rolles; Martin Kirschner; Florian Holtbernd; Mareike Tometten; Tim H Brümmendorf; Fabian Beier
Journal:  Clin Case Rep       Date:  2022-05-05

3.  Acute neurotoxicity following vincristine due to Charcot-Marie-Tooth disease in a young child with medulloblastoma.

Authors:  Trisha Kissoon; Sridharan Gururangan; John Sladky
Journal:  Neurooncol Pract       Date:  2019-03-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.